
• Reported GAAP EPS of $0.04 up 112.12% YoY • Reported revenue of $140.5M up 13.05% YoY • AtriCure projects full year 2026 revenue of $600M to $610M, reflecting 12% to 14% growth, with adjusted EBITDA of $80 million to $82 million, and adjusted EPS of $0.09 to $0.15.
Bullish
AtriCure achieved strong Q4 and full year 2025 revenue growth, driven by expanding product adoption and improved profitability. The company is advancing key innovation and strategic initiatives.
Bearish
AtriCure experienced declines in minimally invasive device revenue and a full year net loss of -$11.4M. The company also faces competition from new technologies and regulatory clearance risks.